Stocks and Investing
Stocks and Investing
Mon, March 13, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Steve Valiquette Initiated (AMED) at Hold and Held Target at $93 on, Mar 13th, 2023
Steve Valiquette of Barclays, Initiated "Amedisys, Inc." (AMED) at Hold and Held Target at $93 on, Mar 13th, 2023.
Steve has made no other calls on AMED in the last 4 months.
There are 7 other peers that have a rating on AMED. Out of the 7 peers that are also analyzing AMED, 2 agree with Steve's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Scott Fidel of "Stephens & Co." Reiterated at Hold and Held Target at $95 on, Thursday, February 16th, 2023
- Whit Mayo of "SVB Leerink" Maintained at Hold with Decreased Target to $85 on, Thursday, January 5th, 2023
These are the ratings of the 5 analyists that currently disagree with Steve
- Jonathan Yong of "Credit Suisse" Reiterated at Buy and Held Target at $115 on, Monday, February 27th, 2023
- Ben Hendrix of "RBC Capital" Maintained at Buy with Decreased Target to $111 on, Tuesday, February 21st, 2023
- Mark Miller of "Benchmark" Maintained at Strong Buy with Decreased Target to $115 on, Thursday, February 16th, 2023
- Bill Sutherland of "Benchmark" Reiterated at Strong Buy and Held Target at $120 on, Monday, February 13th, 2023
- Colin Rusch of "Oppenheimer" Maintained at Buy with Decreased Target to $125 on, Thursday, January 19th, 2023
Contributing Sources